

Financial management of high-cost gene therapies

At QBE, we understand the unique challenge self-funded plan sponsors face when they encounter the significant cost of gene therapy treatment to their health plan.

Advanced, high-cost technologies that provide patients with life changing clinical benefits also create financial strain on a plan sponsor's health spend. As cutting-edge medical treatments evolve, so do the complexities of providing comprehensive coverage.

Recognizing the substantial impact a gene therapy claim can have, QBE's policy provides the assurance of financial protection against catastrophic medical liability and includes the coverage terms required to protect the assets of the plan sponsor's health plan.



Standard & Poor's



A.M. Best*

QBE is a global insurance leader focused on helping customers solve unique risks, so you can focus on what matters most.

Gene therapy innovation embraced, not excluded:

- Our Excess Loss Insurance Policy does not exclude FDA-approved gene therapy treatments. These expenses are treated the same as any other catastrophic expense QBE covers for self-funded health plans.
- There is no additional fee to cover gene therapy expenses.
- Pre-existing condition provisions or authorization requirements are unrestricted.

Financial protection on both incurred and future gene therapy liability:

- QBE will continue to provide our policyholders with our value-added Simultaneous Funding service, protecting the plan sponsor's cashflow when faced with a significant expense to their health plan.
- Gene therapies provide long-term gains with a one-time treatment. With continued proven success in the durability of these treatments, once administered and funded, we view this expense as non-recurring at time of renewal.
- QBE believes in a long-term commitment to our customers when they are faced with short-term catastrophic expenses. Accordingly, our underwriting analysis at renewal will exclude any paid gene therapy claim expense in the current and prior policy periods.
- Through our Rate Stabilization (No New Laser with Rate Cap) Endorsement, we provide our policyholders with stability and predictability by capping renewal premiums and not applying new lasers on known potential gene therapy liabilities at renewal.

QBE is committed to ensuring an innovative and sustainable medical stop loss product offering, delivering comprehensive policy protection to our customers. We take pride in continuing to provide our valued customers with a solution to the new and emerging healthcare landscape, such as those related to gene therapy treatment for rare and challenging diseases.

For more information, please contact your QBE business development leader or policy account manager.

QBE North America

123 Pleasant Street, 3rd Floor
Marblehead, MA 01945
800.742.9279
qbe.com/us

¹'Top 10' claim made based on premiums earned, [2022 NAIC Accident & Health Policy Experience Report](#).

This literature is descriptive only. Actual coverage is subject to the language of the policies as issued. All products and services are written or provided by QBE Insurance Corporation or its affiliates, One QBE Way, Sun Prairie, WI 53596. Products and services may not be available in all jurisdictions. Coverage is subject to actual policy language and the information provided in this document is for general informational purposes and does not constitute an offer to sell or a solicitation. QBE and the links logo are registered service marks of QBE Insurance Group Limited.
© 2025 QBE Holdings, Inc. 856554 (4-25)